ISRCTN65230311
Completed
未知
Efficacy and safety of growth hormone treatment in short children born small for gestational age; effects of growth hormone levels on growth, insulin sensitivity and body composition
Erasmus Medical Center (The Netherlands)0 sites157 target enrollmentJuly 19, 2006
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Small for gestational age (SGA), children with persistent short stature
- Sponsor
- Erasmus Medical Center (The Netherlands)
- Enrollment
- 157
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Children born with a birth length and/or weight \<2 standard devations (SD) for gestational age (Usher McLean)
- •2\. Neonatal period without signs of severe asphyxia (defined as Apgar score \<3 after five minutes), and no serious diseases such as long\-term artificial ventilation and oxygen supply, bronchopulmonary dysplasia or other chronic lung diseases
- •3\. Short stature defined as a height SD score below 2\.5 according to the Dutch National Growth references of 1997
- •4\. Height velocity (cm/year) for chronological age
- •5\. Chronological age at the start of treatment: 3\.00 \- 7\.99 years (boys and girls)
- •6\. Prepubertal signs defined as Tanner stage 1 or testicular volume \<4 ml
- •7\. Well documented growth data from birth up to two years and at least one year before the start of the study
- •8\. Both growth hormone deficient and growth hormone insufficient patients
- •9\. Informed consent
Exclusion Criteria
- •1\. Chromosomal disorders, known syndromes and serious dysmorphic symptoms suggestive for a syndrome that has not yet been described, except for Silver Russell syndrome
- •2\. Coeliac disease and other chronic or serious diseases of the gastrointestinal tract, heart, genitourinary tract, liver, lungs, skeleton, central nervous system, metabolic disease, chronic or recurrent major infectious diseases, nutritional and/or vitamin deficiencies
- •3\. Any endocrine or metabolic disorder such as diabetes mellitus, diabetes insipidus, hypothyroidism, or inborn errors of metabolism, except for growth hormone deficiency (GHD)
- •4\. Use of medications or interventions at this moment or during the previous six months that might have interfered with growth, such as corticosteroids (including high dose of corticosteroid inhalation), sex steroids, growth hormone, or major surgery (particularly of the spine or extremities)
- •5\. Active malignancy or increased risk of leukaemia
- •6\. Serious suspicion of psychosocial dwarfism (emotional deprivation)
- •7\. Expected non\-compliance
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Effects of growth hormone treatment to patients with partial growth hormone deficiency, with special emphasis on acute phase proteins and pro-inflammatory cytokines.EUCTR2005-004478-26-SEKarolinska universitetssjukhuset
Active, not recruiting
Phase 2
Evaluation of Growth Hormone Treatment in adolescence: Effect on body composition, bones, glucose and lipids in patients who were treated with this hormoneRBR-29sg4xgniversidade de São Paulo
Not yet recruiting
Not Applicable
Effects of growth hormone (GH) replacement therapy in GH deficient adult childhood cancer survivors on organ size and microvascularisation of kidney and skin.growth hormone deficiency1002111210038430NL-OMON33094ovo Nordisk50
Completed
Not Applicable
Growth hormone deficiency and clottingISRCTN59234325eeds Teaching Hospitals NHS Trust (UK)140
Not yet recruiting
Phase 3
Investigating the results of adding growth hormone to the ovulation stimulation regimen in microinjection and In Vitro Fertilization in patients with low ovarian reserveIRCT20130603013566N13Vice chancellor for Research,Tabriz University Of Medical Sciences96